FMP

FMP

Enter

FATE - Fate Therapeuti...

photo-url-https://financialmodelingprep.com/image-stock/FATE.png

Fate Therapeutics, Inc.

FATE

NASDAQ

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

3.01 USD

-0.06 (-1.99%)

About

ceo

Mr. J. Scott Wolchko

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the ...

CIK

0001434316

ISIN

US31189P1021

CUSIP

31189P102

Address

12278 Scripps Summit Drive

Phone

858 875 1800

Country

US

Employee

181

IPO Date

Oct 1, 2013

FATE Financial Summary

CIK

0001434316

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

31189P102

ISIN

US31189P1021

Country

US

Price

3.01

Beta

1.84

Volume Avg.

1.63M

Market Cap

342.77M

Shares

-

52-Week

1.63-8.83

DCF

-0.03

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-1.77

P/B

-

Website

https://www.fatetherapeutics.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest FATE News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep